4/A: Actuate Therapeutics Insider Leslie Kreis Amends Form 4 to Correct Stock Price After IPO

Leslie Kreis, a director and 10% owner of Actuate Therapeutics, files an amended Form 4 to correct the stock price reported in a previous filing related to warrant exercises following the company's IPO.

Summary

• This is an amendment to a Form 4 filing related to Actuate Therapeutics.
• The amendment corrects the stock price reported in the original Form 4 filed on August 14, 2024.
• The corrected filing concerns transactions related to the automatic cashless exercise of warrants to purchase common stock in connection with Actuate Therapeutics' IPO.
• The reporting person is Leslie W. Kreis, who is a director and 10% owner of Actuate Therapeutics.
• The transactions involve the withholding of shares to cover the exercise price of the warrants.
• The warrants were held by various Bios Equity Partners entities.
• The corrected price is $8 per share.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (an amendment to correct a previous filing) and does not contain information that would significantly impact sentiment.

Industry Context

Form 4 filings are standard practice and provide transparency into insider transactions, which is important for maintaining market confidence.

Stakeholder Impact

• The correction of the stock price in the Form 4 filing ensures accurate information is available to shareholders and the public.

Key Dates